Literature DB >> 10193735

Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction.

H Schöder1, R Campisi, T Ohtake, C K Hoh, D H Moon, J Czernin, H R Schelbert.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the predictive accuracy of positron emission tomography (PET) blood flow-F-18 fluorodeoxyglucose (FDG) imaging in coronary artery disease (CAD) patients with diabetes mellitus (DM).
BACKGROUND: Positron emission tomography accurately predicts the postrevascularization improvement in left ventricular dysfunction in unselected patients with CAD. In diabetic patients, however, poor myocardial glucose utilization may limit the accuracy of the approach.
METHODS: Forty patients (64+/-10 years old; 19 with DM = group I; 21 without DM = group II) with reduced left ventricular ejection fraction (LVEF = 29+/-6%) were studied with N-13 ammonia and FDG PET before coronary revascularization. Studies were performed after intravenous injection of regular insulin (group I) or oral glucose administration (group II). Blood flow-FDG mismatches and matches were identified by polar map analysis in the three vascular territories of the left anterior descending, left circumflex and right coronary artery. Wall motion and LVEF were assessed by two-dimensional echocardiography before and 158+/-123 days after revascularization.
RESULTS: Of 107 vascular territories analyzed, 46 were classified as mismatch, 29 as match and 32 as normal. The FDG image quality, assessed by F-18 myocardium to blood pool activity ratios, and the predictive accuracy were similar in both groups; presence of a blood flow/FDG mismatch had a sensitivity of 92% (group I) and 94% (group II) and a specificity of 85% (group I) and 79% (group II) for an improvement in regional left ventricular function. A postrevascularization improvement in global left ventricular function was related to the extent of blood flow/FDG mismatch; LVEF increased from 30+/-7% to 35+/-7% (p = 0.017) in patients with one mismatch and from 27+/-4% to 41+/-7% (p < 0.001) in those with two mismatches.
CONCLUSIONS: The predictive accuracy of blood flow/FDG imaging is maintained in patients with DM when a clinically acceptable study protocol, which guarantees good FDG image quality, is used. The extent of a blood flow/metabolism mismatch is correlated with the magnitude of the postrevascularization improvement in global left ventricular function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193735     DOI: 10.1016/s0735-1097(99)00010-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

1.  PET myocardial perfusion and glucose metabolism imaging: Part 2-Guidelines for interpretation and reporting.

Authors:  Heinrich R Schelbert; Robert Beanlands; Frank Bengel; Juhani Knuuti; Marcelo Dicarli; Josef Machac; Randolph Patterson
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

2.  Factors influencing predictive value of FDG imaging for evaluating myocardial viability.

Authors:  Jamshid Maddahi
Journal:  J Nucl Cardiol       Date:  2004 Sep-Oct       Impact factor: 5.952

Review 3.  Imaging techniques in nuclear cardiology for the assessment of myocardial viability.

Authors:  Riemer H J A Slart; Jeroen J Bax; Dirk J van Veldhuisen; Ernst E van der Wall; Rudi A J O Dierckx; Pieter L Jager
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-13       Impact factor: 2.357

Review 4.  Present and future of clinical cardiovascular PET imaging in Europe--a position statement by the European Council of Nuclear Cardiology (ECNC).

Authors:  D Le Guludec; R Lautamäki; J Knuuti; J J Bax; F M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-26       Impact factor: 9.236

5.  Assessment of myocardial viability using F-18 fluorodeoxyglucose/Tc-99m sestamibi dual-isotope simultaneous acquisition SPECT: comparison with Tl-201 stress-reinjection SPECT.

Authors:  Yen-Wen Wu; Por-Jau Huang; Chii-Ming Lee; Yi-Lwun Ho; Lung-Chun Lin; Tzung-Dau Wang; Shoei-Shen Wang; Tony Hsiu-Hsi Chen; Ruoh-Fang Yen
Journal:  J Nucl Cardiol       Date:  2005 Jul-Aug       Impact factor: 5.952

Review 6.  Nuclear cardiac imaging for the assessment of myocardial viability.

Authors:  R H J A Slart; J J Bax; E E van der Wall; D J van Veldhuisen; P L Jager; R A Dierckx
Journal:  Neth Heart J       Date:  2005-11       Impact factor: 2.380

7.  Blood flow, flow reserve, and glucose utilization in viable and nonviable myocardium in patients with ischemic cardiomyopathy.

Authors:  Xiaoli Zhang; Thomas H Schindler; John O Prior; James Sayre; Magnus Dahlbom; Sung-Cheng Huang; Heinrich R Schelbert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-04       Impact factor: 9.236

8.  Incremental predictive value of myocardial scintigraphy with 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Mamoru Nanasato; Haruo Hirayama; Akitada Ando; Satoshi Isobe; Makoto Nonokawa; Yoshimi Kinoshita; Ichiro Nanbu; Mitsuhiro Yokota; Toyoaki Murohara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

9.  Myocardial viability by contrast-enhanced cardiovascular magnetic resonance in patients with coronary artery disease: comparison with gated single-photon emission tomography and FDG position emission tomography.

Authors:  Yen-Wen Wu; Eiji Tadamura; Shotaro Kanao; Masaki Yamamuro; Akira Marui; Masashi Komeda; Masanao Toma; Takeshi Kimura; Kaori Togashi
Journal:  Int J Cardiovasc Imaging       Date:  2007-03-16       Impact factor: 2.357

10.  Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy.

Authors:  Kuan-Yin Ko; Shan-Ying Wang; Ruoh-Fang Yen; Yu-Chien Shiau; Jung-Cheng Hsu; Hao-Yuan Tsai; Chien-Lin Lee; Kuan-Ming Chiu; Yen-Wen Wu
Journal:  J Nucl Cardiol       Date:  2018-08-14       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.